Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787235 | 1.00 | MEN1 (0.42) | MEN1KMT2AHTRA1ALDH1A1CACNA1A | |
| SCHEMBL3053306 | 1.00 | MEN1 (0.42) | MEN1KMT2AHTRA1ALDH1A1CACNA1A | |
| SCHEMBL29548365 | 0.90 | HTRA1 (0.44) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL6787441 | 0.89 | FKBP1A (0.43) | HTRA1POLBNR1H2NR1H3 | |
| SCHEMBL29548830 | 0.87 | NR1H2 (0.46) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL30170293 | 0.87 | NR1H2 (0.46) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL2229858 | 0.86 | POLB (0.46) | POLBL3MBTL1 | |
| SCHEMBL2229857 | 0.86 | POLB (0.46) | POLBL3MBTL1 | |
| SCHEMBL28721184 | 0.83 | HTRA1 (0.54) | MEN1KMT2AHTRA1ALDH1A1CACNA1A | |
| SCHEMBL12589813 | 0.80 | KMT2A (0.44) | MEN1KMT2AHTRA1ALDH1A1CACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7651997-B2 | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070129289-A1 | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | THE TRUSEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1276491-B9 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1276491-B1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7064105-B2 | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1276491-A4 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1276491-A1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001076616-A1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129289-A1 | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | PRAP1, PTMA, DHPS | MEN1 2472/4885KMT2A 3794/4885HTRA1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.